"Le service d'oncologie médicale du CGFL propose aux patients une prise en charge et des traitements adaptés à leur pathologie. L'oncologue médical propose différents types de traitements contre le cancer : chimiothérapie, hormonothérapie, immunothérapie... Des consultations régulières permettent de vérifier le bon déroulement du traitement et la prise en charge d'éventuels effets indésirables, pendant et à la fin des soins."

During the past decade, Centre Georges François Leclerc conducted 316 clinical trials. In the 10-year time frame, 316 clinical trials started and 44 clinical trials were completed, i.e. on average, 13.9% percent of trials that started reached the finish line to date. In the past 5 years, 158 clinical trials started and 25 clinical trials were completed. i.e. 15.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Georges François Leclerc" #1 sponsor was "UNICANCER" with 70 trials, followed by "Centre Georges Francois Leclerc" with 55 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 40 trials sponsored, "Hoffmann-La Roche" with 34 trials sponsored and "Centre Leon Berard" with 34 trials sponsored. Other sponsors include 275 different institutions and companies that sponsored additional 110 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Georges François Leclerc" #1 collaborator was "AstraZeneca" with 24 trials as a collaborator, "National Cancer Institute, France" with 24 trials as a collaborator, "Hoffmann-La Roche" with 10 trials as a collaborator, "Pfizer" with 10 trials as a collaborator and "Roche Pharma AG" with 10 trials as a collaborator. Other collaborators include 272 different institutions and companies that were collaborators in the rest 178 trials.

According to Clinical.Site data, the most researched conditions in "Centre Georges François Leclerc" are "Breast Cancer" (63 trials), "Prostate Cancer" (22 trials), "Metastatic Colorectal Cancer" (17 trials), "Colorectal Cancer" (15 trials) and "Cancer" (14 trials). Many other conditions were trialed in "Centre Georges François Leclerc" in a lesser frequency.

Most popular intervention types in "Centre Georges François Leclerc" are "Drug" (357 trials), "Other" (81 trials), "Radiation" (69 trials), "Procedure" (52 trials) and "Biological" (40 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (23 trials), "Placebo" (23 trials), "Paclitaxel" (21 trials), "Docetaxel" (20 trials) and "fluorouracil" (20 trials). Other intervention names were less common.

The vast majority of trials in "Centre Georges François Leclerc" are 359 trials for "All" genders, 106 trials for "Female" genders and 36 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Georges François Leclerc". 5 are not yet recruiting, 146 are recruiting, 80 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 195 completed trials in Centre Georges François Leclerc, 3 suspended trials, and 43 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Georges François Leclerc, 56 "Phase 1" clinical trials were conducted, 200 "Phase 2" clinical trials and 153 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 88 trials that are defined as “Not Applicable".